Thomas Geisbert, lead UTMB researcher. Credit: The University of Texas Medical Branch at Galveston
An interdisciplinary team from The University of Texas Medical Branch at Galveston and Profectus BioSciences, Inc. has developed a quick-acting vaccine that is both safe and effective with a single dose against the Ebola strain that killed thousands of people in West Africa last year. These findings are detailed in the new edition of Nature.
During 2014, the outbreak of the West African Makona strain of Ebola Zaire virus killed nearly 10,000 and caused worldwide concern. With increasing population growth in West Africa, the frequency of contact between humans and natural Ebola virus hosts such as bats will likely rise, potentially leading to more catastrophic outbreaks.
Many vaccine approaches have shown promise in being able to protect nonhuman primates against Ebola Zaire. In response to the Ebola Zaire outbreak, several of these vaccines have been fast tracked for human use.
One of those vaccines, developed by UTMB and Profectus, has been undergoing testing in the Galveston National Laboratory, the only fully operational Biosafety Level 4 laboratory on an academic campus in the U.S.
"These findings may pave the way for the identification and manufacture of safer, single dose, high efficiency vaccines to combat current and future Ebola outbreaks," said Thomas Geisbert, UTMB professor of Mmicrobiology and Iimmunology. "We are excited at the possibility of helping develop a way to stop this deadly disease. We have a lot of more work to accomplish but it's important to note that this is a big step."
The research team developed a vaccine effective against Ebola Zaire with a single dose in a nonhuman primate model. This new vaccine employs a virus not harmful to humans called vesicular stomatitis virus that had a part of the Ebola virus inserted into it. This "Trojan horse" vaccine safely triggered an immune response against Ebola Zaire.
To address any possible safety concerns associated with this vaccine, the team developed two next generation candidate vaccines that contain further weakened forms of the vaccine. Both of these vaccines produced an approximately ten-fold lower level of virus in the blood compared to the first generation vaccine.
"It was not known whether any of these vaccines could provide protection against the new outbreak West African Makona strain of Ebola Zaire currently circulating in Guinea," said John Eldridge, Chief Scientific Officer-Vaccines at Profectus Biosciences, Inc. "Our findings show that our candidate vaccines provided complete, single dose protection from a lethal amount of the Makona strain of Ebola virus."
Both weakened vaccines have features of the Mayinga strain of Ebola virus, as do most other candidate Ebola Zaire vaccines currently under evaluation. The original 1976 Mayinga strain and the new West African Makona strain are quite similar. The researchers said it was important to test their candidate vaccines on the Makona strain to ensure that even small differences between the strains didn't impact the effectiveness of the vaccine.
Explore further: New Ebola trial vaccine 'safe', researchers report
More information: Single dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus, DOI: 10.1038/nature14428
Medical Xpress on facebook
Related Stories
Experimental Ebola vaccine appears safe, prompts immune response
An early-stage clinical trial of an experimental Ebola vaccine conducted at the National Institutes of Health (NIH) and the Walter Reed Army Institute of Research (WRAIR) found that the vaccine, called VSV-ZEBOV, ...
Gene variant and environment can boost severity of respiratory syncytial virus
A particular genetic mutation combined with an urban environment increases the risk of severe disease in children infected with respiratory syncytial virus (RSV), an international team of investigators has found.
Personalized melanoma vaccines marshal powerful immune response
Personalized melanoma vaccines can be used to marshal a powerful immune response against unique mutations in patients' tumors, according to early data in a first-in-people clinical trial at Washington University ...
Norovirus candidate vaccine induces broad antibody responses in trial participants
A multivalent candidate vaccine elicits broad antibody responses to a range of norovirus strains, including strains not included in the vaccine or previously encountered by participants, according to a new study published ...
Clinical trials of VPM1002 as a tuberculosis vaccine in newborns
The only tuberculosis vaccine currently approved, the Bacillus Calmette-Guérin (BCG) vaccine, protects children from the most severe forms of the disease in most cases but does not provide protection against the most common ...
Chikungunya virus may be coming to a city near you—learn the facts
The mosquito-borne chikungunya virus has been the subject of increasing attention as it spreads throughout South America, Central America, the Caribbean and Mexico. This painful and potentially debilitating ...
Recommended for you
Osteoporosis-related fractures in China expected to double by 2035
The results of the first study using a health economics model to project osteoporosis-related fractures and costs for the Chinese population, shows that the country's healthcare system will face a dramatic rise in costs over ...
Turning to freshwater sources to fight drug-resistant tuberculosis, other infections
The discovery of antibiotics produced by soil fungi and bacteria gave the world life-saving medicine. But new antimicrobials from this resource have become scarce as the threat of drug resistance grows. Now, ...
Total annual hospital costs could be reduced by rapid candidemia identification
A new study describes a model that estimates the economic consequences of using the T2Candida Panel (a novel diagnostic product that provides Candida detection) as an adjunct to the current blood culture-based diagnostic ...
Plotting the elimination of dengue
Dengue is a viral infection spread between humans by Aedes aegypti mosquitoes. Dengue causes flu-like symptoms, including intense headaches and joint pains.
Searching the microbiome for clues to managing inflammatory bowel disease
Sometimes the best medicine is the most basic. Just ask any of the patients with inflammatory bowel disease who are following a new diet designed to reduce the debilitating symptoms of the illness, developed by Barbara Olendzki, ...
Talking turkey: How bird flu outbreaks are playing out
A deadly strain of bird flu has reached the Midwest, killing or requiring hundreds of thousands of turkeys to be euthanized. Some questions and answers about the outbreak:
User comments
Please sign in to add a comment. Registration is free, and takes less than a minute. Read more
Click here to reset your password.
Sign in to get notified via email when new comments are made.
Thomas Geisbert, lead UTMB researcher. Credit: The University of Texas Medical Branch at Galveston
An interdisciplinary team from The University of Texas Medical Branch at Galveston and Profectus BioSciences, Inc. has developed a quick-acting vaccine that is both safe and effective with a single dose against the Ebola strain that killed thousands of people in West Africa last year. These findings are detailed in the new edition of Nature.
During 2014, the outbreak of the West African Makona strain of Ebola Zaire virus killed nearly 10,000 and caused worldwide concern. With increasing population growth in West Africa, the frequency of contact between humans and natural Ebola virus hosts such as bats will likely rise, potentially leading to more catastrophic outbreaks.
Many vaccine approaches have shown promise in being able to protect nonhuman primates against Ebola Zaire. In response to the Ebola Zaire outbreak, several of these vaccines have been fast tracked for human use.
One of those vaccines, developed by UTMB and Profectus, has been undergoing testing in the Galveston National Laboratory, the only fully operational Biosafety Level 4 laboratory on an academic campus in the U.S.
"These findings may pave the way for the identification and manufacture of safer, single dose, high efficiency vaccines to combat current and future Ebola outbreaks," said Thomas Geisbert, UTMB professor of Mmicrobiology and Iimmunology. "We are excited at the possibility of helping develop a way to stop this deadly disease. We have a lot of more work to accomplish but it's important to note that this is a big step."
The research team developed a vaccine effective against Ebola Zaire with a single dose in a nonhuman primate model. This new vaccine employs a virus not harmful to humans called vesicular stomatitis virus that had a part of the Ebola virus inserted into it. This "Trojan horse" vaccine safely triggered an immune response against Ebola Zaire.
To address any possible safety concerns associated with this vaccine, the team developed two next generation candidate vaccines that contain further weakened forms of the vaccine. Both of these vaccines produced an approximately ten-fold lower level of virus in the blood compared to the first generation vaccine.
"It was not known whether any of these vaccines could provide protection against the new outbreak West African Makona strain of Ebola Zaire currently circulating in Guinea," said John Eldridge, Chief Scientific Officer-Vaccines at Profectus Biosciences, Inc. "Our findings show that our candidate vaccines provided complete, single dose protection from a lethal amount of the Makona strain of Ebola virus."
Both weakened vaccines have features of the Mayinga strain of Ebola virus, as do most other candidate Ebola Zaire vaccines currently under evaluation. The original 1976 Mayinga strain and the new West African Makona strain are quite similar. The researchers said it was important to test their candidate vaccines on the Makona strain to ensure that even small differences between the strains didn't impact the effectiveness of the vaccine.
Explore further: New Ebola trial vaccine 'safe', researchers report
More information: Single dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus, DOI: 10.1038/nature14428
Medical Xpress on facebook
Related Stories
Experimental Ebola vaccine appears safe, prompts immune response
An early-stage clinical trial of an experimental Ebola vaccine conducted at the National Institutes of Health (NIH) and the Walter Reed Army Institute of Research (WRAIR) found that the vaccine, called VSV-ZEBOV, ...
Gene variant and environment can boost severity of respiratory syncytial virus
A particular genetic mutation combined with an urban environment increases the risk of severe disease in children infected with respiratory syncytial virus (RSV), an international team of investigators has found.
Personalized melanoma vaccines marshal powerful immune response
Personalized melanoma vaccines can be used to marshal a powerful immune response against unique mutations in patients' tumors, according to early data in a first-in-people clinical trial at Washington University ...
Norovirus candidate vaccine induces broad antibody responses in trial participants
A multivalent candidate vaccine elicits broad antibody responses to a range of norovirus strains, including strains not included in the vaccine or previously encountered by participants, according to a new study published ...
Clinical trials of VPM1002 as a tuberculosis vaccine in newborns
The only tuberculosis vaccine currently approved, the Bacillus Calmette-Guérin (BCG) vaccine, protects children from the most severe forms of the disease in most cases but does not provide protection against the most common ...
Chikungunya virus may be coming to a city near you—learn the facts
The mosquito-borne chikungunya virus has been the subject of increasing attention as it spreads throughout South America, Central America, the Caribbean and Mexico. This painful and potentially debilitating ...
Recommended for you
Osteoporosis-related fractures in China expected to double by 2035
The results of the first study using a health economics model to project osteoporosis-related fractures and costs for the Chinese population, shows that the country's healthcare system will face a dramatic rise in costs over ...
Turning to freshwater sources to fight drug-resistant tuberculosis, other infections
The discovery of antibiotics produced by soil fungi and bacteria gave the world life-saving medicine. But new antimicrobials from this resource have become scarce as the threat of drug resistance grows. Now, ...
Total annual hospital costs could be reduced by rapid candidemia identification
A new study describes a model that estimates the economic consequences of using the T2Candida Panel (a novel diagnostic product that provides Candida detection) as an adjunct to the current blood culture-based diagnostic ...
Plotting the elimination of dengue
Dengue is a viral infection spread between humans by Aedes aegypti mosquitoes. Dengue causes flu-like symptoms, including intense headaches and joint pains.
Searching the microbiome for clues to managing inflammatory bowel disease
Sometimes the best medicine is the most basic. Just ask any of the patients with inflammatory bowel disease who are following a new diet designed to reduce the debilitating symptoms of the illness, developed by Barbara Olendzki, ...
Talking turkey: How bird flu outbreaks are playing out
A deadly strain of bird flu has reached the Midwest, killing or requiring hundreds of thousands of turkeys to be euthanized. Some questions and answers about the outbreak:
User comments
Please sign in to add a comment. Registration is free, and takes less than a minute. Read more
Click here
to reset your password.
Sign in to get notified via email when new comments are made.
0 comments:
Post a Comment